Department of Cardiology, Toronto General Hospital Research Institute, Toronto, ON, Canada.
Ted Rogers Cardiotoxicity Prevention Program, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada.
JNCI Cancer Spectr. 2020 Oct 28;5(1). doi: 10.1093/jncics/pkaa099. eCollection 2021 Feb.
Survivors of adolescent and young adult cancers (AYAs) often live 50 to 60 years beyond their diagnosis. This rapidly growing cohort is at increased risk for cancer- and treatment-related 'late effects' that persist for decades into survivorship. Recognition of similar issues in pediatric cancer survivors has prompted the development of evidence-based guidelines for late effects screening and care. However, corresponding evidence-based guidelines for AYAs have not been developed. We hosted an AYA survivorship symposium for a large group of multidisciplinary AYA stakeholders (approximately 200 were in attendance) at Princess Margaret Cancer Centre (Toronto, Ontario, Canada) to begin addressing this disparity. The following overview briefly summarizes and discusses the symposium's stakeholder-identified high-priority targets for late effects screening and care and highlights knowledge gaps to direct future research in the field of AYA survivorship. This overview, although not exhaustive, is intended to stimulate clinicians to consider these high-priority screening and care targets when seeing survivors in clinical settings and, ultimately, to support the development of evidence-based late effects screening and care guidelines for AYAs.
青少年和年轻成人癌症（AYA）幸存者通常在诊断后存活 50 至 60 年。这一快速增长的人群面临癌症和治疗相关“晚期效应”的风险增加，这些效应在生存期间持续数十年。对儿科癌症幸存者类似问题的认识促使制定了晚期效应筛查和护理的循证指南。然而，针对 AYA 的相应循证指南尚未制定。我们在玛格丽特公主癌症中心（多伦多，安大略省，加拿大）为一大群多学科的 AYA 利益相关者（约有 200 人出席）举办了 AYA 生存研讨会，以开始解决这一差距。以下概述简要总结并讨论了研讨会确定的晚期效应筛查和护理的高优先级目标，并强调了知识空白，以指导 AYA 生存领域的未来研究。虽然不详尽，但本概述旨在鼓励临床医生在临床环境中看到幸存者时考虑这些高优先级的筛查和护理目标，并最终支持为 AYA 制定基于证据的晚期效应筛查和护理指南。
